CERo Therapeutics Holdings, Inc. (CERO)
Nasdaq · Healthcare · Biotechnology
$0.004−20.00%as of Nov 5, 2026, 7:50 AM ET
- Market cap
- $287K
- 52-week range
- $0.003 – $0.135
- 52-week change
- −96.08%
- EPS (trailing)
- $40.34
Fiscal year to Dec 2025
- Net income
- −$19.9M
From the company’s annual report on SEC EDGAR.
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Headquarters: South San Francisco, United States · 8 employees · cero.bio